Study Supported by $2.6 Million FDA Orphan Products Development Grant "We are pleased with these recent study results and that the FDA is continuing to financially support the HyBryte™ program, giving ...
Targets Critical Gaps In CTCL Treatment With Hybryte(TM). Cutaneous T-cell lymphoma, or CTCL, is recognized by clinicians as one of the most difficult cancers to diagnose accurately in its early ...
On Monday, Soligenix, Inc. (NASDAQ:SNGX) said it has opened patient enrollment for its confirmatory Phase 3 study evaluating HyBryte (synthetic hypericin) for cutaneous T-cell lymphoma (CTCL). The ...
(RTTNews) - Citius Oncology, Inc. (CTOR), the oncology subsidiary of Citius Pharmaceuticals Inc. (CTXR) announced the U.S. commercial launch of LYMPHIR, a new immunotherapy for adults with relapsed or ...
MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced new data highlighting the quality-of-life ...
For patients with advanced-stage MF and SS (n=371), the median overall survival from the onset of treatment was higher for patients treated with mogamulizumab (n=72) at 64 months compared with those ...
Citius Oncology Inc. has commercially launched Lymphir, a treatment for Stage I–III cutaneous T-cell lymphoma, the Cranford-based firm announced Dec. 1. In August 2024, the U.S. Food and Drug ...
CRANFORD, N.J., Dec. 1, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc ...
Leading edge artificial intelligence and machine learning platform supports enhanced salesforce targeting and engagement for cutaneous T-cell lymphoma immunotherapy launch "We are committed to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results